Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly
BIIB [NASD]
Biogen Idec Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E37.00 EPS (ttm)6.30 Insider Own0.07% Shs Outstand237.37M Perf Week2.62%
Market Cap55.32B Forward P/E23.52 EPS next Y9.91 Insider Trans-17.60% Shs Float237.18M Perf Month9.55%
Income1.50B PEG2.18 EPS next Q1.90 Inst Own94.61% Short Float1.00% Perf Quarter43.34%
Sales5.64B P/S9.81 EPS this Y14.31% Inst Trans0.50% Short Ratio1.71 Perf Half Y62.38%
Book/sh30.91 P/B7.54 EPS next Y23.26% ROA15.69% Target Price221.41 Perf Year77.13%
Cash/sh2.79 P/C83.41 EPS next 5Y16.98% ROE22.05% 52W Range126.39 - 238.83 Perf YTD59.23%
Dividend- P/FCF33.89 EPS past 5Y23.67% ROI18.16% 52W High-2.62% Beta0.90
Dividend %- Quick Ratio3.76 Sales past 5Y11.71% Gross Margin90.32% 52W Low84.02% ATR7.24
Employees5950 Current Ratio4.16 Sales Q/Q9.53% Oper. Margin35.25% RSI (14)67.49 Volatility3.28% 2.88%
OptionableYes Debt/Eq0.12 EPS Q/Q43.07% Profit Margin26.82% Rel Volume0.78 Prev Close233.07
ShortableYes LT Debt/Eq0.10 EarningsApr 25 BMO Payout0.00% Avg Volume1.39M Price232.58
Recom2.10 SMA205.52% SMA5014.46% SMA20041.87% Volume1,049,163 Change-0.21%
09-May-13Reiterated MKM Partners Neutral $208 → $215
29-Apr-13Reiterated Argus Buy $195 → $250
26-Apr-13Reiterated Canaccord Genuity Buy $206 → $231
26-Apr-13Reiterated Barclays Overweight $210 → $220
23-Apr-13Reiterated Deutsche Bank Buy $170 → $240
15-Apr-13Reiterated Barclays Equal Weight $180 → $210
09-Apr-13Reiterated RBC Capital Mkts Outperform $180 → $215
28-Mar-13Reiterated Stifel Buy $184 → $202
22-Feb-13Reiterated RBC Capital Mkts Outperform $170 → $180
07-Feb-13Reiterated UBS Neutral $157 → $167
07-Feb-13Reiterated Canaccord Genuity Hold $139 → $163
07-Feb-13Reiterated Barclays Overweight $150 → $180
29-Jan-13Reiterated UBS Neutral $148 → $157
25-Jan-13Reiterated Barclays Overweight $145 → $150
18-Dec-12Initiated Canaccord Genuity Hold $144
29-Nov-12Reiterated Argus Buy $155 → $160
05-Oct-12Downgrade Oppenheimer Outperform → Perform
10-Sep-12Downgrade UBS Buy → Neutral $156 → $156
09-Jul-12Reiterated Stifel Nicolaus Buy $144 → $167
09-May-12Reiterated UBS Buy $135 → $148
23-May-13 02:04PM  Amgen Stock Checkup for May at Motley Fool
01:36PM  Elan rejects Royalty's $6.4 billion raised offer Reuters
01:22PM  Elan rejects Royalty's $6.4 bln raised offer at Reuters
12:44PM  Alkermes posts 4Q profit as royalty payments rise AP
12:07PM  Jim Cramer: Buy Biogen Idec, Celgene, Clean Harbors, and This Stock at Wall St. Cheat Sheet
09:35AM  Alex Denner Joins Vivus Activist Slate in Post-Icahn Move at Bloomberg
08:22AM  MS Patients Choose Death Risk With Potent Drug Treatment at Bloomberg
08:06AM  Royalty Pharma eases condition for Elan offer AP
08:04AM  Biogen appoints Spyros Artavanis-Tsakonas as Chief Scientific Officer theflyonthewall.com
08:02AM  InPlay: Biogen Idec appoints Spyros Artavanis-Tsakonas Chief Scientific Officer Briefing.com
08:01AM  Royalty cuts acceptance bar for Elan bid to 50 percent at Reuters
08:00AM  Royalty cuts acceptance bar for Elan bid to 50 pct at Reuters
08:00AM  Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer Business Wire
22-May-13 04:05PM  Another Multiple Sclerosis Winner for Biogen at Motley Fool
04:01PM  Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference Business Wire
02:55PM  Additional Patent for Acorda's Ampyra Zacks
01:18PM  Buy Bristol-Myers, Says Citi; Stock Jumps 7% at Barrons.com
10:43AM  Biogen Idec Stock Hits New 52-Week High (BIIB) at TheStreet
08:05AM  Check Out 5 Big Caps With Long-Term Growth Prospects at Investor's Business Daily
21-May-13 09:07PM  1 Big Pharma Phase 3 Failure at Motley Fool
05:44PM  TripAdvisor, Biogen, Lennar: Stocks Will Danoff Likes at Investor's Business Daily
04:47PM  Stocks Get A Boost From Dovish Fed Remarks at Investor's Business Daily
04:42PM  Biogen submits new MS drug for FDA approval AP
04:10PM  Positive Data on Novo Nordisk's N9-GP Zacks
03:14PM  Biogen submits new MS drug for FDA approval AP
02:22PM  Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Opportunities in Hepatitis C and Genomic Technologies Wall Street Transcript
01:44PM  Flush With Cash, Elan Goes on a Buying Spree at Motley Fool
04:30AM  Biogen Idec Submits Application to FDA for Approval of PLEGRIDY (Peginterferon Beta-1a) in Multiple Sclerosis Business Wire
20-May-13 05:01PM  Teva Bets on Reformulating Old Drugs as Investors Say Show Me at Bloomberg
04:05PM  Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash at Bloomberg
03:27PM  Royalty raises Elan bid, issues ultimatum to shareholders at Reuters
02:59PM  S&P 500 Growth Stocks Portfolio That Can Outperform The Market By A Big Margin at Seeking Alpha
02:55PM  Analysts: J.C. Penney Is In Trouble and 3 More Research Notes to Browse at Wall St. Cheat Sheet
02:33PM  Royalty Pharma increases bid for drugmaker Elan AP
12:01PM  Royalty Pharma Raises Elan Bid to $12.50 a Shae in Cash at Bloomberg
09:40AM  Biogen's Hemophilia BLA Accepted Zacks
19-May-13 02:00PM  Multiple Sclerosis and Hemophilia: This Biotech's Just Getting Started at Motley Fool
18-May-13 08:05AM  IBD 50: Top 5 Medical Stocks Include Celgene, Actavis at Investor's Business Daily
17-May-13 06:53AM  InPlay: Biogen Idec and Genentech have filed for a re-hearing of U.S. Court of Appeals decision in the Arzerra patent infringement case Briefing.com
16-May-13 03:11PM  Data show new Roche leukemia drug may improve on Rituxan at Reuters
01:23PM  Investing in Health Care Innovation: A Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund Wall Street Transcript
01:04PM  AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward at TheStreet
11:06AM  2 Scariest Dividend Stocks in Health Care at Motley Fool
04:40AM  Roche Experimental Leukemia Drug Helps Shrink Tumors at Bloomberg
15-May-13 06:00PM  Roche Experimental Leukemia Drug Helps Shrink Tumors at Bloomberg
05:59PM  Data shows new Roche leukemia drug may improve on Rituxan at Reuters
05:01PM  Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard at TheStreet
12:46PM  Jim Cramer: Buy AOL, Celgene, Biogen, and This Hot Stock Now at Wall St. Cheat Sheet
09:31AM  [video] Cramer's '4 Horsemen of the Apocalypse' for Shorts at CNBC
14-May-13 06:00PM  Jim Cramer's 5 Investing Sweet Spots at CNBC
05:23PM  MainStay Large Cap Growth Nibbles On Apple at Investor's Business Daily
03:30PM  Isis Gets $3.5M Milestone Payment Zacks
10:08AM  Biogen Idec Stock Hits New 52-Week High (BIIB) at TheStreet
08:58AM  Morning Read: Biotech Under the Microscope at Barrons.com
06:10AM  [$$] Biotech Fund: Many Healthy Returns at Barrons.com
02:53AM  Merck KGaA steps up cost savings, boosting profit at Reuters
01:33AM  Today's 3 Best Stocks at Motley Fool
13-May-13 06:10PM  3 Healthcare Stock Stories For Monday Investment Wellness at Wall St. Cheat Sheet
05:40PM  Diversifying Royalties at a Hefty Cost at Motley Fool
05:30PM  Theravance, Glaxo, Elan Star In Biotech Soap Opera at Investor's Business Daily
04:37PM  This Big Hedge Fund Is Bullish On Big Companies; Should You Be? at Seeking Alpha
04:34PM  Stocks End Mixed In Quiet Trade; Stratasys Leads 3D Rally at Investor's Business Daily
04:07PM  A Breather for a Day, as Health Care Stocks Do the Heavy Lifting at New York Times
12:25PM  Biogen says FDA starts hemophilia drug review AP
11:16AM  Theravance Stock Hits High On $1 Billion Elan Deal at Investor's Business Daily
09:41AM  [video] Faber Report: Elan Strikes Deal With Theravance at CNBC
09:38AM  Did Elan Just Overpay On Theravance To Spurn Its Hostile Suitor? at Forbes
08:18AM  Elan's $1 billion drug royalty deal aids bid defense Reuters
07:31AM  InPlay: Biogen Idec announces FDA accepted its biologics license application for first long-lasting factor VIII therapy for Hemophilia A Briefing.com
07:30AM  FDA Accepts Biogen Idecs Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A Business Wire
10-May-13 04:39PM  Cramer: Biotech Makes a Comeback at TheStreet
02:01PM  Analysts: Cisco Valuation is Overly Bearish and 2 Other Research Notes to Check Out at Wall St. Cheat Sheet
01:04PM  Marketers Seek Fix as Email Overwhelms Consumers Big Data Download
01:04PM  Marketers Seek Fix as Email Overwhelms Consumers
12:52PM  Biotech Makes a Comeback TheStreet
10:22AM  Jim Cramer: Buy Nokia, Buy OpenTable, and Buy These 2 Solid Stocks at Wall St. Cheat Sheet
06:48AM  Cramer's Lightning Round - Selling SunTrust Was A Mistake (5/9/13) at Seeking Alpha
06:00AM  'Mad Money' Lightning Round: Buy, Buy, Buy Biogen at TheStreet
09-May-13 06:42PM  Lightning Round: SunTrust, Nokia & More at CNBC
06:40PM  [video] Lightning Round at CNBC
06:10PM  Biotech Stocks Dominate Your Weekly Review List at Investor's Business Daily
08:31AM  Why I stopped using stop loss orders at MarketWatch
08:31AM  Why I stopped using stop loss orders at MarketWatch
08-May-13 10:38AM  Teva Sees NTE Sales at $2 Billion in Five Years, R&D Chief Says at Bloomberg
10:00AM  Narrower-than-Expected Loss at Seattle Genetics Zacks
07-May-13 05:01PM  Biogen Idec Inc (BIIB): Today's Featured Drugs Laggard at TheStreet
04:42PM  3 Bio Companies Facing The Patent Cliff at Seeking Alpha
02:55PM  REUTERS SUMMIT-Biotech firms evolve from targets to acquirers at Reuters
11:56AM  Forbes Earnings Preview: PDL BioPharma at Forbes
09:45AM  The Zacks Analyst Blog Highlights: Bayer, Biogen Idec, Conceptus, Microsoft and J. C. Penney Zacks
06-May-13 06:30PM  Leading Biotechs Act Well But Be Careful Not To Chase at Investor's Business Daily
04:10PM  Bayer Discontinues Hemophilia Study Zacks
02:50PM  Acorda Incurs Loss, Maintains Guidance Zacks
01:04PM  5 Stocks Dragging In The Health Care Sector at TheStreet
12:43PM  Analysts: Whole Foods Concerns are Overdone and 3 Research Notes to Read at Wall St. Cheat Sheet
09:53AM  [video] Cramer's Six in 60: Not Too Late to Buy Biogen at CNBC
03-May-13 01:37PM  Analysts: LinkedIns Guidance Is Conservative and 3 Other Research Notes to Read at Wall St. Cheat Sheet
11:50AM  Biogen Idec Achieves #169 Analyst Rank, Surpassing United Parcel Service at Forbes
11:16AM  Wall Street Transcript Interview with Dr. Jason Kantor, Research Analyst at Credit Suisse Group: High Success Rates and Significant M&A in the Antibody Space Wall Street Transcript
05:59AM  Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance at Seeking Alpha
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise0.003470489May 03 03:10 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale215.391,598344,19350,509May 03 03:07 PM
Clancy Paul JExecutive VP and CFOApr 30Sale224.6614,4893,255,0927,087May 01 03:45 PM
Clancy Paul JExecutive VP and CFOApr 29Sale219.719,1232,004,41421,576May 01 03:45 PM
Mulligan RichardDirectorMar 22Sale176.882,900512,9522,020Mar 25 02:20 PM
SHERWIN STEPHEN ADirectorMar 22Sale176.881,500265,3202,655Mar 25 02:18 PM
Posner Brian SDirectorMar 18Sale174.814,500786,64510,150Mar 19 03:15 PM
Mulligan RichardDirectorMar 13Sale175.387,9801,399,5274,920Mar 13 02:56 PM
PAPADOPOULOS STELIOSDirectorMar 11Option Exercise58.4446,6752,727,46349,950Mar 12 02:22 PM
PAPADOPOULOS STELIOSDirectorMar 11Sale172.2646,6758,040,00314,950Mar 12 02:22 PM
SCANGOS GEORGE AChief Executive OfficerMar 01Sale165.301,598264,14953,705Mar 04 04:40 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.004,281032,720Feb 26 01:23 PM
Pawlicki RaymondSVP, Chief Information OfficerFeb 23Option Exercise0.001,529010,762Feb 26 01:24 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.003,821016,938Feb 26 01:25 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 23Option Exercise0.002,598019,986Feb 26 01:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 13Sale163.391,598261,09755,303Feb 14 02:59 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833065,791Feb 12 05:05 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82406,372Feb 12 05:26 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,692030,170Feb 12 05:24 PM
Pawlicki RaymondSVP, Chief Information OfficerFeb 09Option Exercise0.001,890010,126Feb 12 05:20 PM
ALEXANDER SUSAN HEVP, General CounselFeb 09Option Exercise0.003,909014,392Feb 12 05:12 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,692019,224Feb 12 05:10 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.009,767050,681Feb 12 05:05 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,28405,379Feb 12 05:26 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.002,765026,377Feb 12 05:24 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,34409,326Feb 12 05:22 PM
Pawlicki RaymondSVP, Chief Information OfficerFeb 08Option Exercise0.001,10608,759Feb 12 05:20 PM
ALEXANDER SUSAN HEVP, General CounselFeb 08Option Exercise0.002,165011,185Feb 12 05:12 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.003,487015,665Feb 12 05:10 PM
Pawlicki RaymondSVP, Chief Information OfficerFeb 06Option Exercise49.6510,000496,50017,653Feb 07 01:55 PM
PANGIA ROBERT WDirectorFeb 06Option Exercise66.292,500165,72521,098Feb 07 01:58 PM
PANGIA ROBERT WDirectorFeb 06Sale165.552,500413,87518,598Feb 07 01:58 PM
Pawlicki RaymondSVP, Chief Information OfficerFeb 06Sale165.5510,0001,655,5007,653Feb 07 01:55 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,15908,864Feb 05 06:23 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15908,660Feb 05 04:25 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,15102,151Feb 05 04:23 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 01Option Exercise0.004,58604,586Feb 05 04:22 PM
DENNER ALEXANDER JDirectorDec 27Sale148.363,991592,0864,920Dec 28 10:15 AM
DENNER ALEXANDER JDirectorDec 26Sale148.893,989593,9148,911Dec 28 10:15 AM
SCANGOS GEORGE AChief Executive OfficerNov 01Sale139.422,472344,64051,670Nov 02 03:49 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale149.163,654545,03154,142Oct 02 01:10 PM
PANGIA ROBERT WDirectorSep 17Option Exercise66.295,000331,45023,598Sep 18 05:26 PM
PANGIA ROBERT WDirectorSep 17Sale155.005,000775,00018,598Sep 18 05:26 PM
PANGIA ROBERT WDirectorSep 06Option Exercise66.295,000331,45023,598Sep 10 02:20 PM
PANGIA ROBERT WDirectorSep 06Sale150.005,000750,00018,598Sep 10 02:20 PM
SHERWIN STEPHEN ADirectorSep 04Sale145.902,000291,8004,155Sep 05 03:20 PM
SCANGOS GEORGE AChief Executive OfficerSep 04Sale145.903,654533,11957,796Sep 05 03:17 PM
ALEXANDER SUSAN HEVP, General CounselAug 02Sale142.991,165166,5839,020Aug 03 11:12 AM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale146.303,655534,72761,450Aug 02 03:24 PM
ALEXANDER SUSAN HEVP, General CounselJul 27Option Exercise57.0458,0703,312,15768,255Jul 30 02:58 PM
ALEXANDER SUSAN HEVP, General CounselJul 27Sale150.0058,0708,710,50010,185Jul 30 02:58 PM
SCANGOS GEORGE AChief Executive OfficerJul 17Sale146.042,472361,01165,105Jul 18 03:35 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Option Exercise0.0021,339085,256Jul 17 01:03 PM
SCANGOS GEORGE AChief Executive OfficerJul 02Sale143.501,183169,76163,917Jul 03 10:40 AM
Pawlicki RaymondSVP, Chief Information OfficerJun 19Option Exercise49.5910,000495,90017,653Jun 21 11:41 AM
Pawlicki RaymondSVP, Chief Information OfficerJun 19Sale143.0010,0001,430,0007,653Jun 21 11:41 AM
PANGIA ROBERT WDirectorJun 15Option Exercise36.945,000184,70023,598Jun 18 01:50 PM
ALEXANDER SUSAN HEVP, General CounselJun 15Option Exercise47.8749,8002,383,83859,985Jun 18 01:53 PM
ALEXANDER SUSAN HEVP, General CounselJun 15Sale140.0049,8006,972,00010,185Jun 18 01:53 PM
PANGIA ROBERT WDirectorJun 15Sale140.005,000700,00018,598Jun 18 01:50 PM
Posner Brian SDirectorJun 07Option Exercise71.382,500178,45015,130Jun 11 11:22 AM
Posner Brian SDirectorJun 07Sale135.002,500337,50012,630Jun 11 11:22 AM
Posner Brian SDirectorJun 04Option Exercise71.382,400171,31215,030Jun 05 03:41 PM
PANGIA ROBERT WDirectorJun 04Option Exercise36.945,000184,70021,578Jun 05 03:45 PM
PANGIA ROBERT WDirectorJun 04Sale130.005,000650,00016,578Jun 05 03:45 PM
SHERWIN STEPHEN ADirectorJun 04Sale126.452,500316,1254,135Jun 05 03:43 PM
Posner Brian SDirectorJun 04Sale126.452,400303,48012,630Jun 05 03:41 PM
Pawlicki RaymondSVP, Chief Information OfficerJun 04Sale126.451,068135,0497,653Jun 05 03:39 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale128.631,183152,16965,100Jun 04 04:26 PM
open in yahoo | open in reuters | open in google